Humanigen WKN: A2QEQW ISIN: US4448632038 Kürzel: HGEN Forum: Aktien Thema: Hauptdiskussion

War ebenfalls ein Donnerstag. Passt schon heute

Auf der HP von Humanigen ist allerdings noch nichts online

Gibt es in absehbarer Zeit Neuigkeiten die den Kurs beeinflussen könnten ?

“We have made excellent progress on the strategic realignment announced in July. We have increased the number of sites for the PREACH-M study in Australia of lenzilumab in chronic myelomonocytic leukemia (‘CMML’), a rare blood cancer, and have interest from top oncology centers in the United States. We are on track to enroll the first patient in the RATinG study in the UK of lenzilumab in acute graft versus host disease (‘aGvHD’) and expect dosing soon,” stated Cameron Durrant, Chairman and Chief Executive Officer, Humanigen. “Given the positive results from the company’s LIVE-AIR study and the survival trend observed in the ACTIV-5/BET-B study, we have interest from a global group of leading institutions and research networks to include lenzilumab in their large-scale, multinational studies of COVID-19. Tocilizumab and baricitinib demonstrated mortality benefit following inclusion in such studies despite having failed to do so in smaller studies. We are exploring the requirements for inclusion in these studies and plan to provide an update before the end of 2022. In addition, we are currently assessing requests for investigator-initiated trials (‘IIT’s’) of lenzilumab in combination with CAR-T therapies and plan to continue the development of ifabotuzumab (‘iFab’), an EpAh-3 targeted monoclonal antibody currently in Phase 1 development, as part of an antibody drug conjugate (‘ADC’), for certain solid tumors in Australia.”

Under the realignment plan, the company will deemphasize the deployment of certain resources for the development of lenzilumab for COVID-19. The preliminary topline results from the Accelerating COVID-19 Therapeutic Interventions and Vaccines-5 (“ACTIV-5”) and Big Effect Trial, in the “B” arm of the trial (“BET-B”), referred to as the ACTIV-5/BET-B trial did indicate that lenzilumab demonstrated a positive trend in mortality. The company continues to support National Institutes of Health’s (“NIH’s”) further analysis of the data.

Bei mir steht bei Finanzen.net das heute Zahlen kommen

Seitwärts seit Tagen....

Bei CNBC steht nix

TR schreibt am 10.08, Nasdaq am 11.08 @AirRailey bei den Amis kommt der Monat.Tag.Jahr in der Datumsangabe

Ich glaube am 08.10 und nicht 10.08

Heute kommen Zahlen, oder?

Nochmal nachgelegt

Bei mir muss der Kurs noch etwas in die Knie gehen... Sonst würde ich ja hoch kaufen...🧐🤓

Wenn nein, werd ich auch zufrieden

Bei 0,2 werd ich noch mal nachsenken, wenn es dazu kommen sollte